ClinicalTrials.gg
Not yet recruitingNCT07852377CARBIOMUpdated Oct 1, 2026

Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma

An interventional study of Biological sample collection and immunomonitoring in B Cell Lymphoma and Multiple Mieloma, sponsored by Centre Henri Becquerel. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Centre Henri Becquerel · Not applicable, Interventional, and Basic science

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Lymphoma, B-Cell with a site in France — 20 open to participants now, 36 under way, 9 of them phase 3. Lymphoma, B-Cell · France.

Planned enrollment
62nd of 83
45 · median 103
Started
2026
with 5 others
No phase
7 of 95
3 open now
Primary completion
2027-11
later than 19 of 35 live
Registered
94th of 95
by date
Lead sponsor
3 of 95
Centre Henri Becquerel

Among the 95 studies in Lymphoma, B-Cell with a site in France, this one is the 62nd largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2026, is one of 7 with no phase, reaches primary completion later than 19 of the 35 other live ones, and was the 94th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

20 of the 95 studies in Lymphoma, B-Cell with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Lymphoma, B-Cell with a site in France, or all of them as a file.
02

Study summary

CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints. Up to 45 adults with relapsed or refractory B-cell lymphoma or multiple myeloma who are scheduled to receive standard-of-care anti-CD19 or anti-BCMA CAR-T cells will be enrolled. The study will characterize CAR-positive and endogenous CAR-negative T-cell populations and T-cell receptor clonality at apheresis, in the CAR-T product, at Day 7 +/- 3 days and at Month 1 +/- 7 days. These findings will be related to treatment response, toxicities and relapse during 12 months of follow-up. The study hypothesis is that dynamic immunological and molecular characteristics measured along the CAR-T pathway are associated with early response, toxicity and relapse risk.

Read the detailed description

CARBIOM will enroll up to 45 participants to obtain 40 reinfused and evaluable participants at Month 1: 20 with B-cell lymphoma and 20 with multiple myeloma. CAR-T treatment and all disease-directed care remain standard of care and are not assigned by the study. Research procedures consist mainly of protocol-specific blood and stool sampling and laboratory analyses.

The primary analysis will longitudinally characterize CAR-positive and CAR-negative T-cell subpopulations, including expansion and decline, activation, differentiation, exhaustion, and T-cell receptor repertoire diversity, clonality and persistence. Analyses will use spectral flow cytometry and sequencing at apheresis, in the CAR-T bag before infusion, at Day 7 +/- 3 days and at Month 1 +/- 7 days. These parameters will be compared according to Month 1 response assessed using Lugano 2014 criteria for B-cell lymphomas or International Myeloma Working Group criteria for multiple myeloma.

Secondary and exploratory analyses will describe Month 3 response; 12-month progression-free survival, overall survival and non-relapse mortality; bridging therapy; CAR-T expansion and persistence by routine flow cytometry and digital PCR; cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and prolonged cytopenias; PET-derived tumour burden; apheresis and CAR-T product features; tumour genomics, clonal haematopoiesis, antibiotic exposure and gut microbiota; and will establish a biobank of frozen cells, RNA and DNA for future ancillary analyses.

03

Conditions studied

  • B Cell Lymphoma
  • Multiple Mieloma

Keywords

  • chimeric antigen receptor t-cell therapy
  • relapsed or refractory B-cell lymphoma
  • relapsed or refractory multiple mieloma
  • immunomonitoring
  • T-cell receptor repertoire
  • spectral flow cytometry
  • predictive biomarkers
  • treatment response
  • toxicity
  • relapse
  • gut microbiota
  • clonal haematopoiesis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • B-cell lymphoma or multiple myeloma.
  • Indication for anti-CD19 or anti-BCMA CAR-T cell treatment.
  • Signed .
  • Affiliation to or beneficiary status under a health insurance scheme.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to anti-BCMA bispecific antibodies or need for anti-BCMA bispecific antibodies as bridging therapy before anti-BCMA CAR-T cell administration.
  • Pregnant or breastfeeding.
  • Absence of .
  • Primary central nervous system lymphoma or primary vitreoretinal lymphoma.
  • Body weight below 30 kg.
  • Protected adult or person deprived of liberty under guardianship or curatorship.
  • Inability to understand the study or comply with study constraints for language, psychological, geographical or other reasons.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Other
    CARBIOM cohort

    Adults receiving standard-of-care anti-CD19 or anti-BCMA CAR-T cell therapy undergo protocol-specific biological sampling and longitudinal immunomonitoring. CAR-T treatment is not assigned by the study.

    Procedure: Biological sample collection and immunomonitoring

Interventions

  • ProcedureBiological sample collection and immunomonitoring

    Additional blood samples are collected at protocol-defined time points around standard-of-care CAR-T therapy, and stool samples are collected before lymphodepletion, at Month 1 and at Month 3. Analyses include spectral flow cytometry, T-cell receptor repertoire sequencing, routine flow cytometry, digital PCR, tumour molecular profiling and gut microbiota analyses. Standard-of-care CAR-T treatment is not assigned by the study.

06

What researchers measure

Primary outcomes

  1. Longitudinal CAR-positive and CAR-negative T-cell phenotype and T-cell receptor clonality associated with Month 1 response

    Longitudinal characterisation of expansion and decline kinetics, activation, differentiation and exhaustion profiles, and T-cell receptor repertoire diversity, clonality and persistence by spectral flow cytometry and sequencing. Parameters will be compared between responders and non-responders at Month 1 using Lugano 2014 criteria for B-cell lymphomas or International Myeloma Working Group criteria for multiple myeloma.

    Time frame: Apheresis; CAR-T product before infusion; Day 7 after infusion ; Month 1 after infusion. Therapeutic response is assessed at Month 1.

Secondary outcomes

  1. Secondary imaging outcomes after CAR-T cell infusion

    Measures include Month 3 disease response PET-derived tumour burden

    Time frame: Month 3 after CAR-T cell infusion

  2. Secondary clinical outcomes after CAR-T cell infusion

    12-month progression-free survival, overall survival and non-relapse mortality (in months)

    Time frame: Month 12 after CAR-T cell infusion

  3. Bridge treatment received

    name of bridge treatment received before CAR-T cell infusion

    Time frame: Month 1 after inclusion

  4. secondary immunological outcome after CAR-T cell infusion

    CAR-T expansion and persistence

    Time frame: Month 1 after CAR-T cell infusion

  5. Secondary micobiota outcome

    gut microbiota findings

    Time frame: Month 3 after CAR-T cell infusion

  6. Secondary molecular outcome

    Tumour molecular findings

    Time frame: Inclusion

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Nov 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2026
First posted
Oct 1, 2026
StartEst.
Sep 18, 2026
Primary completionEst.
Nov 2, 2027
CompletionEst.
Nov 2, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07852377
Lead sponsor
Centre Henri Becquerel
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Sep 18, 2026 (estimated)
Primary completion
Nov 2, 2027 (estimated)
Completion
Nov 2, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Vincent Camus, MD, PhD
Contact
vincent.camus@chb.unicancer.fr
+33 2 32 08 29 47
Doriane Richard, PhD
Contact
Doriane.richard@chb.unicancer.fr
+33 2 32 08 29 85

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion